- Home
- BRBR vs VKTX Comparison
BRBR vs VKTX Comparison
Compare BRBR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | VKTX |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRBR | VKTX |
|---|---|---|
| Price | $17.79 | $28.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $43.94 | ★ $89.27 |
| AVG Volume (30 Days) | ★ 4.8M | 3.2M |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $2,321,000,000.00 | N/A |
| Revenue This Year | $6.23 | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | $12.36 | ★ N/A |
| Revenue Growth | ★ 10.59 | N/A |
| 52 Week Low | $17.10 | $18.92 |
| 52 Week High | $79.57 | $43.15 |
Technical Indicators
Market Signals| Indicator | BRBR | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.61 | 47.27 |
| Support Level | $17.10 | $27.17 |
| Resistance Level | $25.75 | $34.38 |
| Average True Range (ATR) | 1.35 | 1.75 |
| MACD | -0.49 | 0.18 |
| Stochastic Oscillator | 7.30 | 51.34 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.